People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Earlier phases of the trial showed promising results, with a single 25mg dose of COMP360 psilocybin, combined with psychological support, significantly reducing depressive symptoms after three weeks, ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...